Since it was founded in 1986, Centaur, Inc.’s business focus has been concentrated in adaptations of proven new technology -- with special emphasis in biotechnology -- converting successes from the human healthcare market to address similar problems in the animal health markets. 

Centaur’s first products of prominence were concentrated in the equine market, and focused on diagnostic technologies that were representative of ‘breakthrough innovations’.  One such product is the Equine Infectious Anemia (EIA) diagnostic that was adapted from the human AIDS test and for which a patent was granted in 1995.